KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Current Leases (2020 - 2026)

Aquestive Therapeutics has reported Current Leases over the past 6 years, most recently at $631000.0 for Q4 2025.

  • For Q4 2025, Current Leases rose 23.73% year-over-year to $631000.0; the TTM value through Dec 2025 reached $631000.0, up 23.73%, while the annual FY2025 figure was $631000.0, 23.73% up from the prior year.
  • Current Leases for Q4 2025 was $631000.0 at Aquestive Therapeutics, up from $601000.0 in the prior quarter.
  • Over five years, Current Leases peaked at $926000.0 in Q1 2022 and troughed at $255000.0 in Q4 2022.
  • A 5-year average of $597200.0 and a median of $555000.0 in 2025 define the central range for Current Leases.
  • Biggest five-year swings in Current Leases: crashed 71.64% in 2022 and later surged 52.94% in 2023.
  • Year by year, Current Leases stood at $899000.0 in 2021, then crashed by 71.64% to $255000.0 in 2022, then soared by 52.94% to $390000.0 in 2023, then soared by 30.77% to $510000.0 in 2024, then grew by 23.73% to $631000.0 in 2025.
  • Business Quant data shows Current Leases for AQST at $631000.0 in Q4 2025, $601000.0 in Q3 2025, and $570000.0 in Q2 2025.